Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation (NASDAQ: IRMD) is focused on MRI-compatible medical devices, and its news flow reflects that specialization. The company regularly issues press releases describing its financial results, product clearances, board changes, and capital allocation decisions. Investors and observers following IRMD news can see how its non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems perform in the marketplace and how management communicates about growth and operations.
Recent news has highlighted record quarterly revenue over multiple consecutive quarters, along with updates on gross margins, domestic and international sales mix, and cash flow from operations. The company also reports on its use of non-GAAP financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, and free cash flow, explaining how these metrics relate to its GAAP results. Dividend announcements, including regular quarterly cash dividends and a special cash dividend, are another recurring theme in iRadimed’s news releases.
Product and regulatory developments are also covered in detail. For example, iRadimed announced FDA 510(k) clearance for its MRidium 3870 IV Infusion Pump System, described as a next-generation MRI-compatible infusion pump with a non-magnetic ultrasonic motor, non-interfering RF emissions, and advanced safety and user interface features. News items also describe the capabilities of the 3880 MRI-compatible patient vital signs monitoring system, which operates in magnetic fields up to 30,000 gauss and is designed to travel with patients between critical care units and MRI suites.
Governance and recognition-related news includes disclosures about changes in the Board of Directors and iRadimed’s inclusion in TIME’s list of America’s Growth Leaders for 2026. Conference participation announcements and earnings call schedules provide additional context for those who want to follow company presentations and management commentary. For anyone tracking IRMD, this news feed offers a consolidated view of its financial performance, product milestones, governance updates, and other corporate developments.
IRADIMED (NASDAQ: IRMD) has been named to Fortune's 100 Fastest Growing Companies list for 2024, ranking 61st. The company, which specializes in non-magnetic MRI-compatible medical devices, earned this recognition based on growth in revenue, profits, and stock returns.
To qualify, companies needed a minimum market cap of $225 million, stock price of at least $5, minimum revenue of $50 million, net income of $10 million, and 20% annual growth in revenue and earnings per share over three years. The ranking considers revenue growth rate, EPS growth rate, and three-year annualized total return through June 28, 2024.
IRADIMED (NASDAQ: IRMD) reported record Q3 2024 revenue of $18.3 million, up 11% year-over-year. The company achieved GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43. Management raised full-year 2024 guidance, expecting revenue between $72.7-73.1 million and GAAP diluted EPS of $1.49-1.52. The company declared a quarterly dividend of $0.15 per share. Domestic sales represented 83% of total revenue, with gross profit margin at 77.4%. The company's MRI-compatible IV infusion pump systems showed strong performance, contributing significantly to the quarter's success.
IRADIMED (NASDAQ: IRMD) has scheduled its 2024 third quarter financial results conference call for October 31st, 2024. The company will release its financial results before market opening, followed by a management-hosted conference call at 11:00 a.m. Eastern Time. Interested participants can register for the call through a provided link, after which they will receive dial-in details and instructions. The call will be available real-time via the internet on the company's website, and a recording will be accessible afterward.
IRADIMED (NASDAQ: IRMD), a leading provider of innovative MRI-compatible medical devices, announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event will take place on October 9, 2024, at the Metropolitan Club in New York.
Iradimed's CFO, Jack Glenn, will be hosting one-on-one meetings with investors during the conference. This participation demonstrates Iradimed's commitment to engaging with the investment community and showcasing its innovative products in the healthcare sector.
The conference provides an excellent platform for Iradimed to connect with potential investors and discuss its advancements in MRI-compatible medical devices. It also offers an opportunity for the company to highlight its market position and growth strategies in the healthcare technology industry.
Iradimed (NASDAQ: IRMD), a leader in MRI-compatible medical devices, announced its participation in the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference. The event will be held at the Yale Club in New York on September 12, 2024. Iradimed's management team will conduct one-on-one meetings with investors during the conference.
IRADIMED (NASDAQ: IRMD) reported record Q2 2024 financial results, with revenue of $17.9 million, up 11.2% year-over-year. The company achieved GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42. Operating income increased by 13.4% to $5.6 million. IRADIMED declared a quarterly cash dividend of $0.15 per share.
For Q3 2024, the company expects revenue between $18.0-$18.2 million and GAAP diluted EPS of $0.34-$0.37. The full-year 2024 guidance remains unchanged, with expected revenue of $72.0-$74.0 million and GAAP diluted EPS of $1.37-$1.47. The strong performance was driven by growth in the IV infusion pump product line and continued strength in gross margins.
IRADIMED (NASDAQ: IRMD) has announced its upcoming 2024 second quarter financial results conference call, scheduled for August 1, 2024. The company will release its financial results before the market opens on that day. The conference call, hosted by Iradimed management, will begin at 12:00 p.m. Eastern Time.
Interested individuals can participate by registering through the provided link. Upon registration, participants will receive a dial-in number, unique pin, and instructions. The call will also be available in real-time via the internet on Iradimed's investor relations website. A recording of the call will be made available on the company's website following its completion.
Iradimed (NASDAQ: IRMD), a leading provider of MRI-compatible medical devices, announced that its common stock will uplist to the Nasdaq Global Market starting June 14, 2024. This move reflects the company's growth and commitment to delivering value to shareholders. Roger Susi, CEO, emphasized that the uplisting enhances Iradimed's market visibility and aligns it with companies of high distinction. Iradimed was previously listed on the Nasdaq Capital Market since its IPO in 2014. The Nasdaq Global Market is known for its rigorous financial and corporate governance standards, including stocks of about 1,450 companies.
IRADIMED reported record revenue of $17.6 million, GAAP diluted EPS of $0.32, and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. The company also declared a regular quarterly cash dividend of $0.15 per share for the second quarter of 2024. The financial results showed an increase in operating income by 18.5% compared to the same period in 2023. The company anticipates strong financial performance for the second quarter and full year of 2024.
Summary not available.